These 10 Firms Crushed The Market Last Week. In this article, we are going to take a look at where Imunon, Inc. (NASDAQ:IMNN) stands against other firms that led last week’s charge. Biotechnology ...

Imunon, Inc. (NASDAQ:IMNN) has completed a private placement, securing $3.25 million in initial funding by selling 7,222,223 ...

Imunon (IMNN) announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 7,222,223 ...

During the quarterly update conference call, management indicated Imunon Inc (IMNN) progresses with pivotal Phase 3 trials while navigating financial hurdles and seeking strategic partnerships.

In the run up to the 2025 annual ASCO meeting, IMUNON (Nasdaq: IMNN) is moving into a Phase III trial with its lead candidate ...

Real-time index price for S&P 500 Index (INX), along with buy or sell indicators, analysis, charts, historical performance, ...

LAWRENCEVILLE, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that an ...

*The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. It is possible that this date will be updated in the future, once the company announces ...

“As we continue to evaluate findings from our Phase 2 OVATION 2 Study, the data show consistently strong improvement in overall and progression-free survival, suggesting that IMNN-001 may drive ...

IMUNON’s Phase 2 OVATION 2 trial of IMNN-001 in advanced ovarian cancer showed a 13-month OS increase (46 vs. 33 months) and ...